Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1987 Aug 15;137(4):285–293.

Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project.

T A Doran, G H Valentine, P Y Wong, G Wielgosz, R J Benzie, H C Soltan, M R Jenner, P A Morland, R J Montgomery, L C Allen, et al.
PMCID: PMC1494022  PMID: 2440547

Abstract

A pilot project of maternal serum alpha-fetoprotein (MSAFP) screening was carried out in Ontario from 1982 to 1985 to examine the feasibility and acceptability of screening a prenatal population for open fetal neural tube defects. A total of 8140 patients at low genetic risk were screened. Patient acceptance was excellent. Blood samples were taken at 16 to 18 weeks' gestation. If the MSAFP level was elevated, the assay was repeated and an ultrasound examination performed. Amniocentesis was offered to 67 women with unexplained persistently elevated levels. The outcome of pregnancy was known in 7473 patients (91.8%). Seven of nine known open fetal neural tube defects were detected. All were confirmed, and no unaffected fetuses were aborted on the basis of the screening results. The rates of perinatal death (6.7%), intrauterine growth retardation (11.7%) and prematurity (23.3%) were significantly higher among the patients with unexplained elevated MSAFP levels than among those with normal levels (p less than 0.001). Of 20 patients with unexplained low levels, 10 subsequently had spontaneous abortions and 10 gave birth to term appropriate-for-gestational-age infants. Seven of nine patients who gave birth to infants with autosomal trisomy had MSAFP values below the median. The findings indicate that MSAFP screening is feasible, accurate and acceptable in a low-risk area.

Full text

PDF
286

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpert W. Human alpha-fetoprotein (AFP) developmental and biological characteristics. UCLA Forum Med Sci. 1978;20:19–26. [PubMed] [Google Scholar]
  2. Brock D. J., Barron L., Duncan P., Scrimgeour J. B., Watt M. Significance of elevated mid-trimester maternal plasma-alpha-fetoprotein values. Lancet. 1979 Jun 16;1(8129):1281–1282. doi: 10.1016/s0140-6736(79)92238-4. [DOI] [PubMed] [Google Scholar]
  3. Brock D. J., Bolton A. E., Monaghan J. M. Prenatal diagnosis of anencephaly through maternal serum-alphafetoprotein measurement. Lancet. 1973 Oct 27;2(7835):923–924. doi: 10.1016/s0140-6736(73)92592-0. [DOI] [PubMed] [Google Scholar]
  4. Brock D. J., Scrimgeour J. B., Steven J., Barron L., Watt M. Maternal plasma alpha-fetoprotein screening for fetal neural tube defects. Br J Obstet Gynaecol. 1978 Aug;85(8):575–581. doi: 10.1111/j.1471-0528.1978.tb14923.x. [DOI] [PubMed] [Google Scholar]
  5. Cuckle H. S., Wald N. J., Lindenbaum R. H. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet. 1984 Apr 28;1(8383):926–929. doi: 10.1016/s0140-6736(84)92389-4. [DOI] [PubMed] [Google Scholar]
  6. Davenport D. M., Macri J. N. The clinical significance of low maternal serum alpha-fetoprotein. Am J Obstet Gynecol. 1983 Jul 15;146(6):657–661. doi: 10.1016/0002-9378(83)91008-6. [DOI] [PubMed] [Google Scholar]
  7. Doran T. A., Cadesky K., Wong P. Y., Mastrogiacomo C., Capello T. Maternal serum alpha-fetoprotein and fetal autosomal trisomies. Am J Obstet Gynecol. 1986 Feb;154(2):277–281. doi: 10.1016/0002-9378(86)90655-1. [DOI] [PubMed] [Google Scholar]
  8. Ferguson-Smith M. A., Rawlinson H. A., May H. M., Tait H. A., Vince J. D., Gibson A. A., Robinson H. P., Ratcliffe J. G. Avoidance of anencephalic and spina bifida births by maternal serum-alphafetoprotein screening. Lancet. 1978 Jun 24;1(8078):1330–1333. doi: 10.1016/s0140-6736(78)92404-2. [DOI] [PubMed] [Google Scholar]
  9. Haddow J. E., Kloza E. M., Smith D. E., Knight G. J. Data from an alpha-fetoprotein pilot screening program in Maine. Obstet Gynecol. 1983 Nov;62(5):556–560. [PubMed] [Google Scholar]
  10. Hunter W. M. Radioimmunoassay and saturation analysis. Preparation and assessment of radioactive tracers. Br Med Bull. 1974 Jan;30(1):18–23. doi: 10.1093/oxfordjournals.bmb.a071161. [DOI] [PubMed] [Google Scholar]
  11. Koontz W. L., Seeds J. W., Adams N. J., Johnson A. M., Cefalo R. C. Elevated maternal serum alpha-fetoprotein, second-trimester oligohydramnios, and pregnancy outcome. Obstet Gynecol. 1983 Sep;62(3):301–304. doi: 10.1097/00006250-198309000-00007. [DOI] [PubMed] [Google Scholar]
  12. Macri J. N., Weiss R. R. Prenatal serum alpha-fetoprotein screening for neural tube defects. Obstet Gynecol. 1982 May;59(5):633–639. [PubMed] [Google Scholar]
  13. Merkatz I. R., Nitowsky H. M., Macri J. N., Johnson W. E. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984 Apr 1;148(7):886–894. doi: 10.1016/0002-9378(84)90530-1. [DOI] [PubMed] [Google Scholar]
  14. Nørgaard-Pedersen B., Bagger P., Bang J., Fischer-Rasmussen W., Gad C., Hasch E., Helkjaer P. E., Jacobsen J. C., Kjeldsen J., Kjaersgaard E. Maternal-serum-alphafetoprotein screening for fetal malformations in 28 062 pregnancies. A four-year experience from a low-risk area. Acta Obstet Gynecol Scand. 1985;64(6):511–514. doi: 10.3109/00016348509156730. [DOI] [PubMed] [Google Scholar]
  15. Roberts C. J., Evans K. T., Hibbard B. M., Laurence K. M., Roberts E. E., Robertson I. B. Diagnostic effectiveness of ultrasound in detection of neural tube defect. The South Wales experience of 2509 scans (1977-1982) in high-risk mothers. Lancet. 1983 Nov 5;2(8358):1068–1069. doi: 10.1016/s0140-6736(83)91049-8. [DOI] [PubMed] [Google Scholar]
  16. Seller M. J., Singer J. D., Coltart T. M., Campbell S. Maternal serum-alpha-fetoprotein levels and prenatal diagnosis of neural-tube defects. Lancet. 1974 Mar 16;1(7855):429–433. [PubMed] [Google Scholar]
  17. Wald N. J., Cuckle H. S., Boreham J., Brett R., Stirrat G. M., Bennett M. J., Turnbull A. C., Solymar M., Jones N., Bobrow M. Antenatal screening in Oxford for fetal neural tube defects. Br J Obstet Gynaecol. 1979 Feb;86(2):91–100. doi: 10.1111/j.1471-0528.1979.tb10574.x. [DOI] [PubMed] [Google Scholar]
  18. Wald N. J., Cuckle H., Brock J. H., Peto R., Polani P. E., Woodford F. P. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet. 1977 Jun 25;1(8026):1323–1332. [PubMed] [Google Scholar]
  19. Wald N., Cuckle H., Stirrat G. M., Bennett M. J., Turnbull A. C. Maternal serum-alpha-fetoprotein and low birth-weight. Lancet. 1977 Aug 6;2(8032):268–270. doi: 10.1016/s0140-6736(77)90953-9. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES